BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design.
Farnaby, W., Koegl, M., Roy, M.J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-Oezguer, J., Riedmueller, C., Gmaschitz, T., Wachter, J., Dank, C., Galant, M., Sharps, B., Rumpel, K., Traxler, E., Gerstberger, T., Schnitzer, R., Petermann, O., Greb, P., Weinstabl, H., Bader, G., Zoephel, A., Weiss-Puxbaum, A., Ehrenhofer-Wolfer, K., Wohrle, S., Boehmelt, G., Rinnenthal, J., Arnhof, H., Wiechens, N., Wu, M.Y., Owen-Hughes, T., Ettmayer, P., Pearson, M., McConnell, D.B., Ciulli, A.(2019) Nat Chem Biol 15: 672-680
- PubMed: 31178587 
- DOI: 10.1038/s41589-019-0294-6
- Primary Citation of Related Structures:  
6HAX, 6HAY, 6HAZ, 6HR2 - PubMed Abstract: 
Targeting subunits of BAF/PBAF chromatin remodeling complexes has been proposed as an approach to exploit cancer vulnerabilities. Here, we develop proteolysis targeting chimera (PROTAC) degraders of the BAF ATPase subunits SMARCA2 and SMARCA4 using a bromodomain ligand and recruitment of the E3 ubiquitin ligase VHL ...